利用健康社会决定因素改善乳腺癌、宫颈癌和结直肠癌筛查的成本效益:系统综述
该研究系统综述了利用健康社会决定因素改善美国乳腺癌、宫颈癌和结直肠癌筛查的经济学评价。结论认为此类干预对服务不足的脆弱人群具有成本效益。
要点
- 利用健康社会决定因素的筛查干预每参与者中位成本为123.87美元。
- 每额外筛查一人中位增量成本为250.37美元。
核心结论
- 利用健康社会决定因素改善乳腺癌、宫颈癌和结直肠癌筛查的干预对美国服务不足的脆弱人群具有成本效益。
主要发现
- 干预每参与者中位成本为123.87美元(四分位间距[IQI],24.44-313.19美元;34个估计值)。
- 每额外筛查一人中位增量成本为250.37美元(IQI,44.67-609.38美元;17个估计值)。
- 模拟最终经济结局的研究中,每人的中位增量成本为122.96美元(IQI,46.96-124.80美元;5个估计值)。
- 模拟最终经济结局的研究中,中位增量筛查率为15%(IQI,14%-20%;5个估计值)。
- 模拟最终经济结局的研究中,每人中位增量QALY为0.04年(IQI,0.006-0.06年;5个估计值)。
临床怎么用
- 研究结果为项目规划者、医疗提供者、实施者和政策制定者实施此类干预提供经济学证据。
- 此类干预可同时促进健康公平和经济效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Screening for breast, cervical, and colorectal cancers in the United States has remained below the Healthy People 2020 goals, with evidence indicating that persistent screening disparities still exist. The US Department of Health and Human Services has emphasized cross-sectoral collaboration in aligning social determinants of health with public health and medical services. Examining the economics of intervening through these novel methods in the realm of cancer screening can inform program planners, health care providers, implementers, and policy makers. OBJECTIVE: To conduct a systematic review of economic evaluations of interventions leveraging social determinants of health to improve screening for breast, cervical, and colorectal cancer to guide implementation. EVIDENCE REVIEW: A systematic literature search for economic evidence was performed in MEDLINE, Embase, PsycINFO, Cochrane Library, Global Health, Scopus, Academic Search Complete, Business Source Complete, EconLit, CINAHL (Cumulative Index to Nursing and Allied Health Literature), ERIC (Education Resources Information Center), and Sociological Abstracts from January 1, 2004, to November 25, 2019. Included studies intervened on social determinants of health to improve breast, cervical, and colorectal cancer screening in the United States and reported intervention cost, incremental cost per additional person screened, and/or incremental cost per quality-adjusted life-year (QALY). Risk of bias was assessed along with qualitative assessment of quality to ensure complete reporting of economic measures, data sources, and analytic methods. In addition, included studies with modeled outcomes had to define structural elements and sources for input parameters, distinguish between programmatic and literature-derived data, and assess uncertainty. FINDINGS: Thirty unique articles with 94 706 real and 4.21 million simulated participants satisfied our inclusion criteria and were included in the analysis. The median intervention cost per participant was $123.87 (interquartile interval [IQI], $24.44-$313.19; 34 estimates). The median incremental cost per additional person screened was $250.37 (IQI, $44.67-$609.38; 17 estimates). Studies that modeled final economic outcomes had a median incremental cost per person of $122.96 (IQI, $46.96-$124.80; 5 estimates), a median incremental screening rate of 15% (IQI, 14%-20%; 5 estimates), and a median incremental QALY per person of 0.04 years (IQI, 0.006-0.06 year; 5 estimates). The median incremental cost per QALY gained of $3120.00 (IQI, $782.59-$33 600.00; 5 estimates) was lower than $50 000, an established, conservative threshold of cost-effectiveness. CONCLUSIONS AND RELEVANCE: Interventions focused on social determinants of health to improve breast, cervical, and colorectal cancer screening appear to be cost-effective for underserved, vulnerable populations in the United States. The increased screening rates were associated with earlier diagnosis and treatment and in improved health outcomes with significant gains in QALYs. These findings represent the latest economic evidence to guide implementation of these interventions, which serve the dual purpose of enhancing health equity and economic efficiency.
引用
- Mohan G, Chattopadhyay S. Cost-effectiveness of Leveraging Social Determinants of Health to Improve Breast, Cervical, and Colorectal Cancer Screening: A Systematic Review. JAMA Oncol. 2020. PMID: 32556187. doi:10.1001/jamaoncol.2020.1460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。